Next Article in Journal
Determination of the Presence of Three Antimicrobials in Surface Water Collected from Urban and Rural Areas
Next Article in Special Issue
Role of Phenothiazines and Structurally Similar Compounds of Plant Origin in the Fight against Infections by Drug Resistant Bacteria
Previous Article in Journal / Special Issue
The Staphylococcus aureus Membrane Protein SA2056 Interacts with Peptidoglycan Synthesis Enzymes
Open AccessReview

Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus

Department of Technology and Biotechnology of Drugs, Faculty of Pharmacy, Jagiellonian University-Medical College / ul. Medyczna 9, 31-688 Cracow, Poland
*
Author to whom correspondence should be addressed.
Received: 4 January 2013 / Revised: 29 January 2013 / Accepted: 30 January 2013 / Published: 5 February 2013
The paper focuses on recent achievements in the search for new chemical compounds able to inhibit multidrug resistance (MDR) mechanisms in Gram-positive pathogens. An analysis of the results of the search for new efflux pump inhibitors (EPIs) for Gram-positive bacteria, which have been performed over the last decade, indicates that almost all efforts are focused on the NorA (MFS) efflux pump in S. aureus. Considering the chemical structures of the NorA EPIs that have been identified, it can be observed that the most active agents belong to the families of compounds possessing conjugated double bonds, e.g., chalcones, piperine-like compounds, N-cinnamoylphenalkylamides or citral amide derivatives. Indole-, dihydronaphthyl-, 2-chloro-5-bromo-phenyl- or piperidine moieties seem to be profitable for the EPI properties, as well. These results, together with an increasing knowledge about a variety of efflux pumps that are involved in MDR of Gram-positive pathogens underline that further search for new EPIs should pay more attention to develop MDR efflux protein targets, including SMR, MATE, ABC or other members of the MFS family. View Full-Text
Keywords: bacterial multidrug resistance; MDR; efflux pump inhibitors; EPIs; NorA bacterial multidrug resistance; MDR; efflux pump inhibitors; EPIs; NorA
Show Figures

Figure 1

MDPI and ACS Style

Handzlik, J.; Matys, A.; Kieć-Kononowicz, K. Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus. Antibiotics 2013, 2, 28-45. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics2010028

AMA Style

Handzlik J, Matys A, Kieć-Kononowicz K. Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus. Antibiotics. 2013; 2(1):28-45. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics2010028

Chicago/Turabian Style

Handzlik, Jadwiga; Matys, Anna; Kieć-Kononowicz, Katarzyna. 2013. "Recent Advances in Multi-Drug Resistance (MDR) Efflux Pump Inhibitors of Gram-Positive Bacteria S. aureus" Antibiotics 2, no. 1: 28-45. https://0-doi-org.brum.beds.ac.uk/10.3390/antibiotics2010028

Find Other Styles

Article Access Map by Country/Region

1
Only visits after 24 November 2015 are recorded.
Search more from Scilit
 
Search
Back to TopTop